Keith Burkhart
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Keith Burkhart has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Jeffrey Brent
University of Colorado School of Medicine , Aurora , Colorado, USA , ucdenver.edu
4 shared publications - Kim Aldy
Baylor University Medical Center , Dallas , Texas, USA , baylor.edu
4 shared publications Paul Wax
American College of Medical Toxicology, Phoenix, AZ, United States
4 shared publications- Albert Dahan
Centre for Human Drug Research, 2333CL Leiden, The Netherlands
2 shared publications David G. Strauss
Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland
2 shared publications- Jeffry Florian
Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research U.S. Food and Drug Administration Silver Spring Maryland USA
2 shared publications
Latest Publications
- 18 March 2026
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 145 (1) , 98-110
Effect of Paroxetine or Escitalopram Coadministered with Oxycodone versus Oxycodone Alone on Ventilation during Hypercapnia: A Randomized Clinical Trial
Background: Opioid-induced respiratory depression remains a critical public safety concern. Previous clinical findings demonstrated decreased hypercapnic ventilation after 5 days when paroxetine, a selective serotonin reuptake inhibitor (SSRI), was administered alone or with oxycodone. However, uncertainty remained whether chronic use of SSRIs could cause similar respiratory effects. This study investigated whether chronic use of paroxetine and another SSRI, escitalopram, led to a similar decrease in ventilatory response to hypercapnia. Methods: In this randomized, double-blind, three-period crossover trial, healthy participants were administered one of the following: 40 mg paroxetine from days 1 to 6 and 60 mg from days 7 to 21, 20 mg escitalopram from days 1 to 6 and 30 mg from days 7 to 21, and placebo from days 1 to 21. A dose of 10 mg oxycodone was coadministered on days 6, 12, and 21. Hyperoxic–hypercapnic ventilation was measured using Duffin’s rebreathing. Results: Of the 27 participants, 22 (81%) completed the trial. Paroxetine and escitalopram both significantly decreased hyperoxic–hypercapnic ventilation when coadministered with oxycodone compared to oxycodone alone on day 21 (paroxetine mean difference, −6.5 l/min; one-sided 97.5% CI, −∞ to −3.1; P < 0.001; escitalopram mean difference, −5.5 l/min; one-sided 97.5% CI, −∞ to −2.1; P = 0.001) and when administered alone compared to placebo on day 20 (paroxetine mean difference, −6.5 l/min; one-sided 97.5% CI, −∞ to −2.1; P = 0.003; escitalopram mean difference, −6.9 l/min; one-sided 97.5% CI, −∞ to −2.5; P = 0.002). Conclusions: Both paroxetine and escitalopram, alone and coadministered with oxycodone, decrease hypercapnic ventilation after 21 days, suggesting that SSRIs may have a class effect on hypercapnic ventilation that persists with chronic use.
- 18 March 2026
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 145 (1) , 98-110
Effect of Paroxetine or Escitalopram Coadministered with Oxycodone versus Oxycodone Alone on Ventilation during Hypercapnia: A Randomized Clinical Trial
Background: Opioid-induced respiratory depression remains a critical public safety concern. Previous clinical findings demonstrated decreased hypercapnic ventilation after 5 days when paroxetine, a selective serotonin reuptake inhibitor (SSRI), was administered alone or with oxycodone. However, uncertainty remained whether chronic use of SSRIs could cause similar respiratory effects. This study investigated whether chronic use of paroxetine and another SSRI, escitalopram, led to a similar decrease in ventilatory response to hypercapnia. Methods: In this randomized, double-blind, three-period crossover trial, healthy participants were administered one of the following: 40 mg paroxetine from days 1 to 6 and 60 mg from days 7 to 21, 20 mg escitalopram from days 1 to 6 and 30 mg from days 7 to 21, and placebo from days 1 to 21. A dose of 10 mg oxycodone was coadministered on days 6, 12, and 21. Hyperoxic–hypercapnic ventilation was measured using Duffin’s rebreathing. Results: Of the 27 participants, 22 (81%) completed the trial. Paroxetine and escitalopram both significantly decreased hyperoxic–hypercapnic ventilation when coadministered with oxycodone compared to oxycodone alone on day 21 (paroxetine mean difference, −6.5 l/min; one-sided 97.5% CI, −∞ to −3.1; P < 0.001; escitalopram mean difference, −5.5 l/min; one-sided 97.5% CI, −∞ to −2.1; P = 0.001) and when administered alone compared to placebo on day 20 (paroxetine mean difference, −6.5 l/min; one-sided 97.5% CI, −∞ to −2.1; P = 0.003; escitalopram mean difference, −6.9 l/min; one-sided 97.5% CI, −∞ to −2.5; P = 0.002). Conclusions: Both paroxetine and escitalopram, alone and coadministered with oxycodone, decrease hypercapnic ventilation after 21 days, suggesting that SSRIs may have a class effect on hypercapnic ventilation that persists with chronic use.
- Open Access
- 21 February 2025
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 134 (4) , 1170-1180
Effect of midazolam co-administered with oxycodone on ventilation: a randomised clinical trial in healthy volunteers
- 21 February 2025
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 134 (4) , 1170-1180
Open AccessEffect of midazolam co-administered with oxycodone on ventilation: a randomised clinical trial in healthy volunteers
- 10 January 2024
- Published by Springer Nature in Drugs
- Vol. 84 (2) , 209-217
Remdesivir Discontinuation Decisions Based on Thresholds of Aminotransferase in an Observational Registry
Background Remdesivir is an antiviral approved by the US Food and Drug Administration (FDA) for treatment of coronavirus disease 2019 (COVID-19), and aminotransferase elevation is commonly reported. Thresholds to be considered for discontinuation due to alanine aminotransferase (ALT) elevation differ between the FDA and European Medicines Agency (EMA). The primary objective was to describe aminotransferase thresholds being used in real-world practice for discontinuation of remdesivir in patients with COVID-19, and compare them with labeled recommendations. Methods This study used a descriptive design based on an ongoing national registry of adverse events, the FDA ACMT COVID-19 ToxIC (FACT) pharmacovigilance project, with 17 participating health systems in the USA. Cases were identified retrospectively for an 18-month period (23 November 2020–18 May 2022). Classification of discontinuation as premature and due to aminotransferases was based on chart documentation by the treating team. Results Of 1026 cases in the FACT registry, 116 cases were included with supplemental data forms completed for aminotransferase elevation with remdesivir, defined a priori for inclusion as ALT doubling or increasing by ≥ 50 U/L. ALT was elevated prior to remdesivir in 47% and increased above baseline during dosing by a median of 92 U/L [interquartile range (IQR) 51–164, max 8350]. Remdesivir was discontinued early in 37 (31.9%) patients due to elevated aminotransferases. The ALT threshold for premature discontinuation was median 200 U/L (IQR 145–396, range 92–5743). Among patients with premature discontinuation of remdesivir for aminotransferase elevation, only 21.6% met FDA criteria to consider discontinuation, and 40.5% met prior EMA criteria to consider discontinuation. Conclusion In this descriptive study of real-world practice in the USA, clinicians are overall making more conservative treatment decisions than are recommended for consideration in approved drug labeling of discontinuation, with wide variation in the aminotransferase thresholds being used.
- 10 January 2024
- Published by Springer Nature in Drugs
- Vol. 84 (2) , 209-217
Remdesivir Discontinuation Decisions Based on Thresholds of Aminotransferase in an Observational Registry
Background Remdesivir is an antiviral approved by the US Food and Drug Administration (FDA) for treatment of coronavirus disease 2019 (COVID-19), and aminotransferase elevation is commonly reported. Thresholds to be considered for discontinuation due to alanine aminotransferase (ALT) elevation differ between the FDA and European Medicines Agency (EMA). The primary objective was to describe aminotransferase thresholds being used in real-world practice for discontinuation of remdesivir in patients with COVID-19, and compare them with labeled recommendations. Methods This study used a descriptive design based on an ongoing national registry of adverse events, the FDA ACMT COVID-19 ToxIC (FACT) pharmacovigilance project, with 17 participating health systems in the USA. Cases were identified retrospectively for an 18-month period (23 November 2020–18 May 2022). Classification of discontinuation as premature and due to aminotransferases was based on chart documentation by the treating team. Results Of 1026 cases in the FACT registry, 116 cases were included with supplemental data forms completed for aminotransferase elevation with remdesivir, defined a priori for inclusion as ALT doubling or increasing by ≥ 50 U/L. ALT was elevated prior to remdesivir in 47% and increased above baseline during dosing by a median of 92 U/L [interquartile range (IQR) 51–164, max 8350]. Remdesivir was discontinued early in 37 (31.9%) patients due to elevated aminotransferases. The ALT threshold for premature discontinuation was median 200 U/L (IQR 145–396, range 92–5743). Among patients with premature discontinuation of remdesivir for aminotransferase elevation, only 21.6% met FDA criteria to consider discontinuation, and 40.5% met prior EMA criteria to consider discontinuation. Conclusion In this descriptive study of real-world practice in the USA, clinicians are overall making more conservative treatment decisions than are recommended for consideration in approved drug labeling of discontinuation, with wide variation in the aminotransferase thresholds being used.
- 2 December 2023
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 61 (12) , 1065-1067
Methanol poisonings from contaminated hand sanitizers identified by the United States Food and Drug Administration
- 2 December 2023
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 61 (12) , 1065-1067
Methanol poisonings from contaminated hand sanitizers identified by the United States Food and Drug Administration
- 15 August 2023
- Published by Springer Nature in Journal of Medical Toxicology
- Vol. 19 (4) , 381-388
Adverse Events in Pregnant Patients Treated with Coronavirus Disease 2019 Therapeutics
Background Pregnant patients are at high risk of maternal and fetal complications from Coronavirus Disease 2019 (COVID-19) infections. The COVID-19 pandemic prompted a surge in the development and repurposing of therapies for the SARS-CoV-2 virus. Evidence is sparse on the efficacy and safety of these therapies in pregnant patients. Our objective was to describe adverse events (AEs) to COVID-19 therapeutics in pregnant patients. Methods This was a case series of AEs reported to the FDA ACMT COVID-19 ToxIC (FACT) Pharmacovigilance Project between November 23, 2020, and June 28, 2022. FACT is an ongoing toxicosurveillance project at 17 sites to proactively identify and report AEs associated with COVID-19 therapeutics. Abstracted information includes demographics, case narratives, exposure details, clinical information, pregnancy details, treatments, and outcomes. Results Forty-six COVID-19-positive pregnant patients who developed AEs following COVID-19 therapeutics were reported to the FACT Pharmacovigilance Project over 19 months. The most reported medications were remdesivir in 22 patients (47.8%) and casirivimab/imdevimab in 8 patients (17.4%). Four patients (8.7%) had life-threatening clinical manifestation, and 16 patients (34.8%) required intervention to prevent permanent damage. The most common maternal and fetal events were elevated serum alanine aminotransferase (26.1%) and non-reassuring fetal heart patterns (20.0%), respectively. Conclusions This case series reports AEs of elevated serum alanine aminotransferase, maternal bradycardia, maternal hypothermia, non-reassuring fetal heart patterns, and emergent or unplanned cesarean sections following administration of several COVID-19 therapeutics. This study was not designed to definitely identify causation, and further study is needed to evaluate the causal role of these therapeutics in AEs affecting pregnant COVID-19 patients.
- 15 August 2023
- Published by Springer Nature in Journal of Medical Toxicology
- Vol. 19 (4) , 381-388
Adverse Events in Pregnant Patients Treated with Coronavirus Disease 2019 Therapeutics
Background Pregnant patients are at high risk of maternal and fetal complications from Coronavirus Disease 2019 (COVID-19) infections. The COVID-19 pandemic prompted a surge in the development and repurposing of therapies for the SARS-CoV-2 virus. Evidence is sparse on the efficacy and safety of these therapies in pregnant patients. Our objective was to describe adverse events (AEs) to COVID-19 therapeutics in pregnant patients. Methods This was a case series of AEs reported to the FDA ACMT COVID-19 ToxIC (FACT) Pharmacovigilance Project between November 23, 2020, and June 28, 2022. FACT is an ongoing toxicosurveillance project at 17 sites to proactively identify and report AEs associated with COVID-19 therapeutics. Abstracted information includes demographics, case narratives, exposure details, clinical information, pregnancy details, treatments, and outcomes. Results Forty-six COVID-19-positive pregnant patients who developed AEs following COVID-19 therapeutics were reported to the FACT Pharmacovigilance Project over 19 months. The most reported medications were remdesivir in 22 patients (47.8%) and casirivimab/imdevimab in 8 patients (17.4%). Four patients (8.7%) had life-threatening clinical manifestation, and 16 patients (34.8%) required intervention to prevent permanent damage. The most common maternal and fetal events were elevated serum alanine aminotransferase (26.1%) and non-reassuring fetal heart patterns (20.0%), respectively. Conclusions This case series reports AEs of elevated serum alanine aminotransferase, maternal bradycardia, maternal hypothermia, non-reassuring fetal heart patterns, and emergent or unplanned cesarean sections following administration of several COVID-19 therapeutics. This study was not designed to definitely identify causation, and further study is needed to evaluate the causal role of these therapeutics in AEs affecting pregnant COVID-19 patients.
- 10 May 2022
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 60 (8) , 942-946
Ivermectin associated adverse events in the treatment and prevention of COVID-19 reported to the FACT pharmacovigilance project
In August 2021, the Centers for Disease Control and Prevention (CDC) released a health alert following the rapid increase in ivermectin prescriptions and reports of severe illness associated with u...
- 10 May 2022
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 60 (8) , 942-946
Ivermectin associated adverse events in the treatment and prevention of COVID-19 reported to the FACT pharmacovigilance project
In August 2021, the Centers for Disease Control and Prevention (CDC) released a health alert following the rapid increase in ivermectin prescriptions and reports of severe illness associated with u...